FDA Set Low Standards for Nicotine Product Approval

Aug.12.2022
FDA Set Low Standards for Nicotine Product Approval
FDA sets low review standards for tobacco companies in determining the safety of nicotine products.

I'm sorry, but "smolaw11" is not a phrase or sentence that requires translation as it is not written in any language. It appears to be a username or a code. Please provide the correct text for me to translate to standard journalistic English.


In an article for Filter, Alex Norcia explained that the US Food and Drug Administration (FDA) has set a lower standard for review of nicotine products in its Center for Tobacco Products (CTP) to determine their suitability for preserving public health than for companies submitting tobacco product applications before they go to market.


Filter has cited documents obtained through the Freedom of Information Act, which describe procedures such as batching and bracketing that allow CTP to apply conclusions to product categories rather than individual evaluations. According to Alex Norcia, "Despite the extremely burdensome bureaucratic demands placed on applicants, the agency is pleased to have found ways to complete its paperwork.


It is evident that the FDA allows itself to take effective shortcuts, but it denies applicants," said Clive Bates, Director of The Counterfactual, in an interview with Filter Magazine.


The issue at hand is that the FDA's extensive process is a considerable waste of time and resources for applicants, but ultimately, it is something that the FDA evaluators cannot manage. Without this shortcut, the PMTA process would become a nightmare for human resources. Therefore, the FDA allows itself to achieve the efficiency it should provide to applicants by blending and packaging thousands of almost identical products.


Statement:


This article is compiled from third-party information and is intended for industry-related exchanges and learning.


This article does not represent the viewpoints of 2FIRSTS and we cannot confirm the authenticity or accuracy of its content. The translation of this article is only for industry-related research and exchange.


Due to limitations in translation proficiency, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains full alignment with the Chinese government on any statements and positions related to domestic, Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA Filing Shows RIF Notices for 229 CTP Employees Were Largely Rescinded
FDA Filing Shows RIF Notices for 229 CTP Employees Were Largely Rescinded
A court declaration signed by FDA official Melanie M. Keller on March 24, 2026 detailed the status of previously issued reduction-in-force notices affecting employees at the Center for Tobacco Products (CTP).
Apr.01 by 2FIRSTS.ai
Breaking: Smoore Shares Fall More Than 16% Intraday in Morning Trade After Results Release, Investor Presentation
Breaking: Smoore Shares Fall More Than 16% Intraday in Morning Trade After Results Release, Investor Presentation
Smoore International (6969.HK) released its 2025 results on March 17 and held an investor presentation on the morning of March 18. In morning trade on March 18, the company’s shares fell more than 16% intraday, hitting a low of HK$9.94.
Mar.18 by 2FIRSTS.ai
Product | 30ml E-Liquid, 40,000 Puffs, and Three Power Settings: OXBAR Launches New DTL Product ROVOTA
Product | 30ml E-Liquid, 40,000 Puffs, and Three Power Settings: OXBAR Launches New DTL Product ROVOTA
E-cigarette brand OXBAR has launched its new DTL e-cigarette, the OXBAR ROVOTA, on its official website. The product contains 30ml of e-liquid and is officially rated for up to approximately 40,000 puffs. It has a nicotine strength of 6mg and offers around 15 flavor options. The device is equipped with a 1400mAh battery, supports Type-C charging, features a 0.4Ω dual mesh coil, and supports three power settings of 20W, 30W, and 40W.
Mar.31 by 2FIRSTS.ai
More Than 500 Stores in Russia’s Nizhny Novgorod Region Voluntarily Stop Selling Vapes
More Than 500 Stores in Russia’s Nizhny Novgorod Region Voluntarily Stop Selling Vapes
According to the Nizhny Novgorod regional government, 550 stores in the region have voluntarily removed vapes and e-liquids from their product assortments. Regional officials said a public offer encouraging businesses to self-restrict vape sales has been in place since September 2025, and that a large retail chain with more than 40 outlets in Nizhny Novgorod joined the initiative. The regional government also said a federal ban on vape sales is expected in the near future.
Apr.15 by 2FIRSTS.ai
Philip Morris Japan Unveils TEREA “Blossom Pearl” for IQOS ILUMA
Philip Morris Japan Unveils TEREA “Blossom Pearl” for IQOS ILUMA
Philip Morris Japan announced that it will launch “TEREA Blossom Pearl,” a new tobacco stick for IQOS ILUMA, on May 11. The new product will expand the TEREA lineup to 27 variants. It features a capsule menthol flavor with strawberry and subtle herbal notes and is priced at JPY 620, or about USD 4.14 based on an assumed rate of 1 JPY = 0.00668 USD. The exchange-rate source should be verified and added.
Apr.28 by 2FIRSTS.ai
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai